A Phase I/II Trial of Romidepsin, Rituximab and Lenalidomide (R3) in Relapsed/Refractory B Cell Lymphomas Including Transformed Follicular Lymphoma

Trial Profile

A Phase I/II Trial of Romidepsin, Rituximab and Lenalidomide (R3) in Relapsed/Refractory B Cell Lymphomas Including Transformed Follicular Lymphoma

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab (Primary) ; Romidepsin (Primary)
  • Indications Acute lymphoblastic leukaemia; B cell lymphoma; Burkitt's lymphoma; Follicular lymphoma; Granulomatosis; Hairy cell leukaemia; Large cell carcinoma; MALT lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Testicular cancer; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Aug 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 07 Jan 2016 Planned initiation date changed from 1 Nov 2014 to 1 Jun 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top